DYAI
Price
$0.99
Change
+$0.02 (+2.06%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
29.79M
61 days until earnings call
FATE
Price
$1.60
Change
+$0.26 (+19.40%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
183.41M
54 days until earnings call
Interact to see
Advertisement

DYAI vs FATE

Header iconDYAI vs FATE Comparison
Open Charts DYAI vs FATEBanner chart's image
Dyadic International
Price$0.99
Change+$0.02 (+2.06%)
Volume$100
Capitalization29.79M
Fate Therapeutics
Price$1.60
Change+$0.26 (+19.40%)
Volume$18.8K
Capitalization183.41M
DYAI vs FATE Comparison Chart
Loading...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYAI vs. FATE commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYAI is a Hold and FATE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (DYAI: $0.97 vs. FATE: $1.34)
Brand notoriety: DYAI and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYAI: 37% vs. FATE: 39%
Market capitalization -- DYAI: $29.79M vs. FATE: $183.41M
DYAI [@Biotechnology] is valued at $29.79M. FATE’s [@Biotechnology] market capitalization is $183.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYAI’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • DYAI’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYAI’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 6 bullish TA indicator(s).

  • DYAI’s TA Score: 5 bullish, 3 bearish.
  • FATE’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, FATE is a better buy in the short-term than DYAI.

Price Growth

DYAI (@Biotechnology) experienced а -6.28% price change this week, while FATE (@Biotechnology) price change was +1.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

DYAI is expected to report earnings on Aug 06, 2025.

FATE is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($183M) has a higher market cap than DYAI($29.8M). FATE YTD gains are higher at: -18.788 vs. DYAI (-44.571). DYAI has higher annual earnings (EBITDA): -7.42M vs. FATE (-176.58M). FATE has more cash in the bank: 279M vs. DYAI (9.92M). DYAI has less debt than FATE: DYAI (5.37M) vs FATE (85.3M). FATE has higher revenues than DYAI: FATE (13.6M) vs DYAI (3.37M).
DYAIFATEDYAI / FATE
Capitalization29.8M183M16%
EBITDA-7.42M-176.58M4%
Gain YTD-44.571-18.788237%
P/E RatioN/AN/A-
Revenue3.37M13.6M25%
Total Cash9.92M279M4%
Total Debt5.37M85.3M6%
FUNDAMENTALS RATINGS
DYAI vs FATE: Fundamental Ratings
DYAI
FATE
OUTLOOK RATING
1..100
422
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
9252
P/E GROWTH RATING
1..100
68100
SEASONALITY SCORE
1..100
n/a20

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (17) in the Biotechnology industry is significantly better than the same rating for DYAI (94). This means that FATE’s stock grew significantly faster than DYAI’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DYAI (100). This means that FATE’s stock grew similarly to DYAI’s over the last 12 months.

FATE's SMR Rating (94) in the Biotechnology industry is in the same range as DYAI (96). This means that FATE’s stock grew similarly to DYAI’s over the last 12 months.

FATE's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for DYAI (92). This means that FATE’s stock grew somewhat faster than DYAI’s over the last 12 months.

DYAI's P/E Growth Rating (68) in the Biotechnology industry is in the same range as FATE (100). This means that DYAI’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DYAIFATE
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 24 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTNSX13.030.02
+0.15%
Russell Inv Tax-Managed Intl Eq S
LIRSX9.36N/A
N/A
Lord Abbett International Value R4
SMRPX10.28N/A
N/A
Westwood Salient MLP & Engy Infras Ultr
SBQAX13.16N/A
N/A
AmericaFirst Alpha Trends Factor Class A
AASOX16.43N/A
N/A
Alger Small Cap Growth I-2

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
N/A
MDGL - DYAI
29%
Poorly correlated
-1.87%
FATE - DYAI
28%
Poorly correlated
-5.63%
SNPX - DYAI
27%
Poorly correlated
+3.19%
AUPH - DYAI
24%
Poorly correlated
+1.19%
CGTX - DYAI
24%
Poorly correlated
-5.04%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-5.63%
ALLO - FATE
57%
Loosely correlated
N/A
CRBU - FATE
55%
Loosely correlated
-3.54%
CRSP - FATE
54%
Loosely correlated
+1.37%
CCCC - FATE
52%
Loosely correlated
-4.87%
NTLA - FATE
52%
Loosely correlated
-1.30%
More